We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
- Authors
Melero, Ignacio; Berman, David M.; Aznar, M. Angela; Korman, Alan J.; Gracia, José Luis Pérez; Haanen, John; Pérez Gracia, José Luis
- Abstract
Immunotherapy has now been clinically validated as an effective treatment for many cancers. There is tremendous potential for synergistic combinations of immunotherapy agents and for combining immunotherapy agents with conventional cancer treatments. Clinical trials combining blockade of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) may serve as a paradigm to guide future approaches to immuno-oncology combination therapy. In this Review, we discuss progress in the synergistic design of immune-targeting combination therapies and highlight the challenges involved in tailoring such strategies to provide maximal benefit to patients.
- Subjects
IMMUNOTHERAPY; CANCER treatment; CLINICAL trials; CYTOTOXIC T lymphocyte-associated molecule-4; PROGRAMMED cell death 1 receptors
- Publication
Nature Reviews Cancer, 2015, Vol 15, Issue 8, p457
- ISSN
1474-175X
- Publication type
journal article
- DOI
10.1038/nrc3973